Psoriasis Center, Department of Dermatology, Venerology and Allergology, University Hospital of Schleswig-Holstein, Campus Kiel, Germany.
J Dtsch Dermatol Ges. 2011 Feb;9(2):94-8. doi: 10.1111/j.1610-0387.2010.07514.x. Epub 2010 Sep 24.
In addition to topical monotherapy for mild and systemic monotherapy for moderate to severe psoriasis, combination therapy plays an important role in daily practice. Although clinical trials almost exclusively evaluate monotherapy regimens, in real life psoriasis patients are usually treated with combination therapies. All combinations are used, topical/topical, topical/UV-light, topical/systemic or UV-light/systemic. Often not only two but more drugs/therapies are combined. Not every combination provides additive or synergistic effects. Some combinations are not possible and may be regarded as contraindications. Data on a benefit-risk-assessment are much more sparse in medical literature as compared to monotherapies. We summarize current knowledge about the use of combination therapies in psoriasis on the basis of published literature in the form of a table to show which combinations are possible, useful or which can not be recommended. This provides a quick overview of available options.
除了轻度银屑病的局部单一疗法和中重度银屑病的系统单一疗法外,联合治疗在日常实践中也具有重要作用。虽然临床试验几乎完全评估单一疗法方案,但在现实生活中,银屑病患者通常接受联合治疗。所有联合治疗都在使用,包括局部/局部、局部/紫外线光疗、局部/系统治疗或紫外线光疗/系统治疗。通常不仅联合使用两种药物,而且还会联合使用三种甚至更多药物。并非每种联合治疗都能提供相加或协同作用。有些联合治疗是不可能的,甚至可能被视为禁忌。与单一疗法相比,药物联合治疗的获益-风险评估数据在医学文献中要少得多。我们根据已发表的文献,以表格的形式总结了目前关于银屑病联合治疗的知识,以显示哪些联合治疗是可行的、有用的,哪些是不可推荐的。这为您提供了一个快速了解可用选择的方法。